EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TGF ‐β Blockade With SB525334 Enhances B7 ‐ H3 CAR ‐ γδT Cell Efficacy Against Glioblastoma

Yang Zhu iD, Zijian Han iD, Zijing Zhou, Yinqiang Sui, Yang Zhang, Zuoyu Jiang, Qinzhi E, Xuewen Zhang, Weichao Wang, Yingbo Hou, Jiaming Du, Yi Tang und 6 weitere

Journal of Cellular and Molecular Medicine · 2026

DOI: 10.1111/jcmm.71089 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2026. Verfasst von Yang Zhu und 17 weiteren Autor:innen. Beteiligte Einrichtung: The Fourth Affiliated Hospital of Soochow University, Suzhou, China. Hauptthemen laut MEDLINE: Glioblastoma, Transforming Growth Factor beta, Imidazoles, Immunotherapy, Adoptive. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Science and Technology Resource Sharing Service Platform Project, Suzhou Medical and Health Innovation Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Transforming growth factor‐beta (TGF‐β) signalling promotes glioblastoma (GBM) immunosuppression and therapy resistance. Although CAR‐γδT therapy has shown promising efficacy in hematologic malignancies, its application to solid tumours—particularly GBM—is impeded by multiple factors, including a highly immunosuppressive tumour microenvironment, inefficient T‐cell infiltration, T‐cell exhaustion driven by inhibitory pathways such as TGF‐β, and antigen heterogeneity. Bioinformatics analyses further corroborate that TGFB1 is significantly upregulated in GBM and correlates with poor prognosis, highlighting TGF‐β as a pivotal mediator of therapeutic resistance. This study aimed to evaluate whether SB525334, a selective TGF‐β receptor inhibitor, can enhance the efficacy and persistence of CAR‐γδT cells in GBM. We demonstrate that SB525334 selectively enhances CAR‐γδT cell function and antitumour efficacy by alleviating TGF‐β–mediated immunosuppression and T‐cell exhaustion while promoting immune activation within the GBM microenvironment. The combination treatment significantly reduced tumour cell viability (approximately 40%–50% residual viability) compared to CAR‐γδT therapy alone (70%–85% residual viability), indicating a clear synergistic effect. Unlike broad‐spectrum inhibitors, SB525334 sustains CAR‐γδT proliferative capacity and effector function under chronic antigen stimulation, remodels the immunosuppressive tumour microenvironment, and promotes a pro‐inflammatory immune signature. Our findings establish a combination strategy to overcome immunosuppressive barriers that limit current CAR‐γδT therapies in solid tumours. By maintaining T‐cell function and remodelling the tumour immune microenvironment, TGF‐β1 small‐molecule inhibitors show potential as translational adjuvants to broaden the clinical applicability of CAR‐γδT cell immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaTransforming Growth Factor betaImidazolesImmunotherapy, AdoptiveReceptors, Chimeric AntigenBrain NeoplasmsHumansAnimalsTumor MicroenvironmentCell Line, TumorT-Cell ExhaustionMiceReceptors, Transforming Growth Factor betaSignal TransductionT-LymphocytesQuinoxalines

Stichwörter der Autor:innen

CAR‐γδT cell therapySB525334TGF‐β signallingcombination therapyglioblastoma (GBM)tumour microenvironment (TME)

Substanzen

Transforming Growth Factor betaImidazolesReceptors, Chimeric AntigenReceptors, Transforming Growth Factor beta6-(2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)quinoxalineQuinoxalines

Autor:innen und Institutionen

  • The Fourth Affiliated Hospital of Soochow University, Suzhou, China.
  • Unicet Biotech, Beijing, China.

ORCID-Profile: Yang Zhu, Zijian Han

Förderung

  • National Natural Science Foundation of China
  • National Science and Technology Resource Sharing Service Platform Project
  • Suzhou Medical and Health Innovation Project
  • Gusu Talent Program
  • Suzhou Industrial Park Healthcare Talent Support Initiative
  • Clinical Priority Disease Diagnosis and Treatment Program

Zitieren

APA

Zhu, Y., Han, Z., Zhou, Z., Sui, Y., Zhang, Y., Jiang, Z., E, Q., Zhang, X., Wang, W., Hou, Y., Du, J., Tang, Y., Dong, H., Xu, Y., Sun, R., Li, C., Li, X., & Huang, Y. (2026). TGF ‐β Blockade With SB525334 Enhances B7 ‐ H3 CAR ‐ γδT Cell Efficacy Against Glioblastoma. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.71089

Vancouver

Zhu Y, Han Z, Zhou Z, Sui Y, Zhang Y, Jiang Z, et al. TGF ‐β Blockade With SB525334 Enhances B7 ‐ H3 CAR ‐ γδT Cell Efficacy Against Glioblastoma. Journal of Cellular and Molecular Medicine. 2026. doi:10.1111/jcmm.71089

BibTeX
@article{Zhu2026,
  author = {Zhu, Yang and Han, Zijian and Zhou, Zijing and Sui, Yinqiang and Zhang, Yang and Jiang, Zuoyu and E, Qinzhi and Zhang, Xuewen and Wang, Weichao and Hou, Yingbo and Du, Jiaming and Tang, Yi and Dong, Hanmiao and Xu, Yeyang and Sun, Ruoyu and Li, Chenyang and Li, Xuetao and Huang, Yulun},
  title = {TGF ‐β Blockade With SB525334 Enhances B7 ‐ H3 CAR ‐ γδT Cell Efficacy Against Glioblastoma},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2026},
  doi = {10.1111/jcmm.71089}
}
Kostenlos starten →